// STATE LEGISLATION TRACKER

Washington SB 5166: Making 2023-2025 fiscal biennium second supplemental operating appropriations.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: In committee

State: Washington
Bill: SB 5166
Session: 2025-2026
Filed: 2025-01-08
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Washington SB5166 is a state budget bill that adjusts 2023-2025 operating appropriations across agencies. Based on the title, available subjects, and status, it does not appear to directly regulate peptides, prescribing, telehealth, compounding, FDA 503A/503B activity, controlled substances, or prescription monitoring.

Key Points

No clear peptide-specific provisions are visible from the title or subjects
No apparent change to compounded peptide access or off-label prescribing
No apparent scope change for NPs, naturopaths, or telehealth clinicians
Could indirectly affect agencies through funding, but no peptide impact is identifiable

What to Watch For

Note Watch budget amendments for health-agency funding that could affect enforcement or licensing capacity.

Note No direct peptide, compounding, telehealth, or prescribing language is apparent from the available bill metadata.

Note Because this is an appropriations bill, any relevant impact would likely come from specific budget provisos.

Where the Bill Stands

The bill was reintroduced and retained in its current status after referral to the Senate Ways & Means Committee.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws